# Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

> **NCT05808322** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ropeginterferon alfa-2b
- **PROCEDURE:** SOC

## Key facts

- **NCT ID:** NCT05808322
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-15
- **Primary completion:** 2024-05-16
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05808322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05808322, "Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05808322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*